Yang Xu

Yang Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJiawei Zhang
Jiawei Zhang
YGYichao Gan
Yichao Gan
HLHongzhi Li
Hongzhi Li
JYJie Yin
Jie Yin
XHXin He
Xin He
WHWendong Huang
Wendong Huang
Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly toxic, and typically fail clinical trials. One alternative approach is to develop non-ATP competitive inhibitors; they disrupt interactions between CDK2 and either its partners or substrates, resulting in specific inhibition of CDK2 activities. In this report, we identify two potential druggable pockets located in the protein-protein interaction interface (PPI) between CDK2 and Cyclin A. To target the potential druggable pockets, we perform a LIVS in silico screening of a library containing 1925 FDA approved drugs. Using this approach, homoharringtonine (HHT) shows high affinity to the PPI and strongly disrupts the interaction between CDK2 and cyclins. Further, we demonstrate that HHT induces autophagic degradation of the CDK2 protein via tripartite motif 21 (Trim21) in cancer cells, which is confirmed in a leukemia mouse model and in human primary leukemia cells. These results thus identify an autophagic degradation mechanism of CDK2 protein and provide a potential avenue towards treating CDK2-dependent cancers.

1 June 2022 in Cancer Communications
Verified
Journal Article
Open access
YXYang Xu
Yang Xu
PLPing Li
Ping Li
YLYang Liu
Yang Liu
DXDijia Xin
Dijia Xin
WLWen Lei
Wen Lei
WQWenbin Qian
Wenbin Qian
Over the last two decades, several epi‐drugs, immune checkpoint inhibitors (ICIs) and adoptive cell therapies have received clinical approval for use in certain types of cancer. However, monotherapy with epi‐drugs or ICIs has shown limited efficacy in most cancer patients. Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion, suggesting that epi‐drugs can potentially synergize with immunotherapy. In this review, we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy, called epi‐immunotherapy, and focus on an update of current clinical trials in both hematological and solid malignancies. Furthermore, we outline the future challenges and strategies in the field of cancer epi‐immunotherapy.

21 June 2019 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SLShu Li
Shu Li
ZWZhan Wang
Zhan Wang
ZWZhaoxing Wu
Zhaoxing Wu
HZHaifeng Zhuang
Haifeng Zhuang
YXYang Xu
Yang Xu

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
SLShu Li
Shu Li
ZWZhan Wang
Zhan Wang
LLLiming Lin
Liming Lin
ZWZhaoxing Wu
Zhaoxing Wu
QYQingfeng Yu
Qingfeng Yu
YXYang Xu
Yang Xu
BCL6 (3q27) rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma (DLBCL). Previously, studies on the association between BCL6 rearrangement and DLBCL outcome remain controversial. Here we systematically reviewed the literature to identify the prognostic significance of BCL6 rearrangement in DLBCL. Meta-analytic methods are used to obtain pooled estimates of the association between BCL6 rearrangement and prognosis in DLBCL patients treated with different chemotherapy regimens. A total of 22 studies are enrolled in the cohort, involving 3037 patients. BCL6 rearrangement is verified to be negatively associated with overall survival (OS) (HR=1.36, p=0.000), but not with progression-free survival (PFS). Moreover, the subgroup analyses show that BCL6 rearrangement is prognostic only in DLBCLs treated with rituximab-containing regimens.

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
FGFeiqiong Gao
Feiqiong Gao
JHJianlai Hu
Jianlai Hu
JZJiawei Zhang
Jiawei Zhang
YXYang Xu
Yang Xu
Objective: Lymphocyte monocyte ratio (LMR) has been considered as a prognostic factor in patients with lymphoma, which focused on diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). Recently, many relevant clinical studies have been published with inconsistent results. To gain a more comprehensive view of the prognostic value of LMR, we conducted a meta-analysis on the significance of peripheral LMR in all subtypes of lymphoma.

8 January 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
FGFeiqiong Gao
Feiqiong Gao
JZJiawei Zhang
Jiawei Zhang
JHJianlai Hu
Jianlai Hu
LLLiming Lin
Liming Lin
YXYang Xu
Yang Xu